Jeffrey Libson

Cooley advised Tourmaline Bio, a late-stage clinical biotechnology company, on its merger agreement with Talaris Therapeutics, including a concurrent private placement.

Cooley advised Veralox Therapeutics on its $16.6 million Series A funding round. Partners Geoffrey Starr and Jeff Libson led the Cooley team advising Veralox, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs.

Cooley advised Immunome on its $39 million initial public offering of 3,250,000 shares of common stock. Immunome, whose securities now trade on the Nasdaq Capital Market under the symbol “IMNM,” is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics. Partners Jeffrey Libson and Ryan Sansom led the Cooley team.

Cooley advised Palladio Biosciences on its $20 million Series B financing. Partners Jeffrey Libson and Geoff Starr led the Cooley team advising Palladio Biosciences, which is a developer of novel therapeutics designed to offer medicines for orphan drug diseases of the kidney.

Cooley advised underwriters on Passage Bio’s $216 million initial public offering of 12,000,000 shares of common stock. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC acted as the joint book-running managers for the offering. Chardan acted as co-manager for the offering. Passage Bio’s securities now trade on the Nasdaq Global Select Market under the symbol “PASG.” Partners Brent Siler. Div Gupta, Jeffrey Libson and Brian Leaf led the Cooley team